Header Logo

Search Results (393)

MatchTypeWhy
Usmani, SaadPerson Why?
Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.Academic Article Why?
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Academic Article Why?
Epstein, MaraPerson Why?
? light chain-expressing hematogones in a patient with??-restricted CLL and multiple myeloma on?daratumumab therapy.Academic Article Why?
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.Academic Article Why?
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.Academic Article Why?
Addressing the disparities: the approach to the African American patient with multiple myeloma.Academic Article Why?
Adenovirus vector-based purging of multiple myeloma cells.Academic Article Why?
An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.Academic Article Why?
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.Academic Article Why?
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.Academic Article Why?
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.Academic Article Why?
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.Academic Article Why?
Bone Health and Survival in Women With Multiple Myeloma.Academic Article Why?
Per Page    Page  of 27last Nextnext
Prev
Search Criteria
  • Multiple Myeloma
Filter by Type
_
Click "Why?" to see why an item matched the search.